The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.
F. R. Mauro
No relevant relationships to disclose
S. Ciolli
No relevant relationships to disclose
F. Di Raimondo
No relevant relationships to disclose
G. Del Poeta
No relevant relationships to disclose
F. Forconi
No relevant relationships to disclose
A. Cuneo
No relevant relationships to disclose
A. Cortellezzi
No relevant relationships to disclose
F. Nobile
No relevant relationships to disclose
M. Brugiatelli
No relevant relationships to disclose
M. Massaia
No relevant relationships to disclose
S. Molica
No relevant relationships to disclose
L. Trentin
No relevant relationships to disclose
R. Rizzi
No relevant relationships to disclose
L. Orsucci
No relevant relationships to disclose
M. A. Mura
No relevant relationships to disclose
A. Alietti
Employment or Leadership Position - Roche
E. J. Runggaldier
Employment or Leadership Position - Roche
E. Gamba
Employment or Leadership Position - Roche (U)
A. Guarini
No relevant relationships to disclose
R. Foa
Consultant or Advisory Role - Roche